This study provides strong evidence of efficacy of a novel CDK9 inhibitor in preclinical models of esophageal adenocarcinoma, supporting a role of targeted inhibition of CDK9 as sensitizer to the radiation in a clinical trial of esophageal adenocarcinoma. The gene discussed is CDK9; the disease is esophageal adenocarcinoma.